Patents by Inventor Keith A Rose

Keith A Rose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6673347
    Abstract: Protein and polypeptide derivatives and their salts are claimed characterized in that a protein or polypeptide is conjugated via an intermediate grouping containing at least one radical of the formula —C(R)═N— (or —N═C(R)—) or —CH(R)—NH— (or —NH—CH(R)—), wherein R is hydrogen or a hydrocarbon residue which may be substituted, with the same or a different protein or polypeptide, with a reporter group or a cytotoxic agent as well as a process for their preparation and the novel intermediates therefor.
    Type: Grant
    Filed: May 12, 1994
    Date of Patent: January 6, 2004
    Assignee: Gryphon Therapeutics
    Inventors: Robin Ewart Offord, Keith Rose
  • Patent number: 6663869
    Abstract: A homogeneous polyoxime composition is provided, in which the polyoxime molecules present comprise a first organic baseplate molecule, which is a polypeptide, wherein the baseplate molecule is linked to at least two second organic molecules, which may be the same or different from one another. In the compositions, the linkages between the baseplate and said organic molecules are oxime linkages formed by reaction of an orthogonal reactive group on each the organic molecules with a complementary orthogonal reactive group on the baseplate.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: December 16, 2003
    Assignee: Gryphon Therapeutics, Inc.
    Inventors: Keith Rose, Robin E. Offord
  • Publication number: 20030228274
    Abstract: Provided are chains of precise length and methods for their preparation. These chains are formed by the reaction of a derivative of a diacid and a diamine in a stepwise manner on a support. One of the reactants contains a water soluble oligomer, preferably polyethylene glycol. These chains are then used to chemically modify target macromolecules such as biologically important polypeptides.
    Type: Application
    Filed: March 6, 2003
    Publication date: December 11, 2003
    Applicant: Gryphon Sciences
    Inventor: Keith Rose
  • Publication number: 20030177079
    Abstract: Methods and systems are provided for managing a financial account in which account information is maintained, including a set of account parameter values and a specification of a default account processing strategy. Account usage information is received for the financial account and is used in combination with the account parameter values to make a determination whether to override at least a portion of the account processing strategy. In addition to implementing the override, the set of account parameter values may be changed.
    Type: Application
    Filed: December 17, 2002
    Publication date: September 18, 2003
    Applicant: First Data Corporation
    Inventors: Steve R. Krajewski, Keith A. Rose, Rebecca J. Cash, Molly Plozay, Richard L. Savage, Tod O. Brockley, Jeffrey S. Harden, Kenneth Algiene, Henry Abelman
  • Publication number: 20030135031
    Abstract: This invention relates to a process for purifying a polypeptide, a capture tag useful for purifying a polypeptide and a periodate-cleavable amino acid derivative useful for purifying a polypeptide.
    Type: Application
    Filed: October 18, 2002
    Publication date: July 17, 2003
    Inventors: Keith Rose, Matteo Villain, Jean Vizzanova
  • Patent number: 6552167
    Abstract: Provided are chains of precise length and methods for their preparation. These chains are formed by the reaction of a derivative of a diacid and a diamine in a stepwise manner on a support. One of the reactants contains a water soluble oligomer, preferably polyethylene glycol. These chains are then used to chemically modify target macromolecules such as biologically important polypeptides.
    Type: Grant
    Filed: August 23, 1999
    Date of Patent: April 22, 2003
    Assignee: Gryphon Therapeutics, Inc.
    Inventor: Keith Rose
  • Patent number: 6217873
    Abstract: Provided by this invention are essentially homogeneous, defined compositions of matter and hetero-polyoximes of defined structure comprising a baseplate structure having a plurality of oxime bonds, wherein each oxime bond links a specifically active molecule to the baseplate. Also provided are novel baseplates having a plurality of oxime forming complementary reactive groups and novel specifically reactive molecules having an oxime forming complementary reactive group. Also provided by this invention are methods of preparing these novel compositions of matter by chemoselectively ligating via oxime bond formation a complementary orthogonal reactive group on the baseplate to a complementary reactive orthogonal group on a specifically active molecule. Methods of using these defined compositions of matter as well as pharmaceutical compositions comprising these defined compositions of matter and methods of their use are also provided by this invention.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: April 17, 2001
    Assignee: Gryphon Sciences
    Inventors: Keith Rose, Robin E. Offord
  • Patent number: 6174530
    Abstract: Provided by this invention are essentially homogeneous, defined compositions of matter comprising a baseplate structure having a plurality of oxime bonds, wherein each oxime bond links a specifically active molecule to the baseplate. Also provided are novel baseplates having a plurality of oxime forming complementary reactive groups and novel specifically reactive molecules having an oxime forming complementary reactive group. Also provided by this invention are methods of preparing these novel compositions of matter by chemoselectively ligating via oxime bond formation a complementary orthogonal reactive group on the baseplate to a complementary reactive orthogonal group on a specifically active molecule. Methods of using these defined compositions of matter as well as pharmaceutical compositions comprising these defined compositions of matter and methods of their use are also provided by this invention.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: January 16, 2001
    Assignee: Gryphon Sciences
    Inventors: Keith Rose, Robin Ewart Offord
  • Patent number: 6001364
    Abstract: Provided by this invention are defined compositions of hetero-polyoximes of defined structure comprising a baseplate structure having a plurality of oxime bonds, wherein each oxime bond links a specifically active molecule to the baseplate. Also provided are novel baseplates having a plurality of oxime forming complementary reactive groups and novel specifically reactive molecules having an oxime forming complementary reactive group. Also provided by this invention are methods of preparing these novel compositions of matter by chemoselectively ligating via oxime bond formation a complementary orthogonal reactive group on the baseplate to a complementary reactive orthogonal group on a specifically active molecule. Methods of using these defined compositions of matter as well as pharmaceutical compositions comprising these defined compositions of matter and methods of their use are also provided by this invention.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: December 14, 1999
    Assignee: Gryphon Sciences
    Inventors: Keith Rose, Robin E. Offord
  • Patent number: 5830852
    Abstract: The invention is based on the discovery of a pharmaceutical preparation for use in gene therapy which includes a therapeutic nucleic acid associated with Insulin-NHCO--CH.sub.2 --O--N.dbd.CH--C-Lys.sub.18 -Cys(S-Pyridyl)-OH in combination with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: November 3, 1998
    Assignee: Cobra Therapeutics, Ltd.
    Inventors: David R. Thatcher, Robin E. Offord, Keith Rose, Hubert F. Gaertner
  • Patent number: 5272253
    Abstract: Targeted drug conjugates which enable a large number of molecules of drug to be directed to a cell by a single molecule of antibody are provided. The invention also provides intermediates for the synthesis of such conjugates and cytotoxic drugs modified in accordance with the cluster concept of the invention.
    Type: Grant
    Filed: July 1, 1991
    Date of Patent: December 21, 1993
    Assignee: Eli Lilly and Company
    Inventors: Gary A. Koppel, Robin E. Offord, Keith Rose, William L. Scott
  • Patent number: 4830624
    Abstract: Disclosed is a battery connector for attaching an electrical cable to the terminal post of a battery. The connector has a hole penetrating therethrough which is adapted to fit around the terminal post. The interior surface of the hole bears a threading helix having a diameter less than that of the terminal post for screwing said connector onto said terminal post.
    Type: Grant
    Filed: February 9, 1988
    Date of Patent: May 16, 1989
    Inventors: Keith A. Rose, Ramon J. Ascencio